MedTrace Logo

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

NCT02784171 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2024-12-10

Study results available
· View outcomes & findings →

Summary

Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.

Conditions

Interventions

DRUG

Cisplatin

DRUG

Pemetrexed

DRUG

Pembrolizumab

Sponsors & Collaborators

  • National Cancer Institute, Naples

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Quincy Chu · Cross Cancer Institute, Edmonton Alberta Canada

  • Francesco Perrone · National Cancer Institute of Naples, Italy

  • Laurent Greillier Marseille · Hopital Nord, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-11
Primary Completion
2024-10-11
Completion
2024-10-11

Countries

  • Canada
  • France
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784171 on ClinicalTrials.gov